It’s a prescription drug used to treat moderate to severe plaque psoriasis in adults. The active ingredient in Ilumya is tildrakizumab-asmn. (The active ingredient is what makes the drug work.) Ilumya is a biologic medication (which means it’s made from living cells). Ilumya is given as a subcutaneous injection (an injection under your skin).
What are the most common side effects of Ilumya?
The most common side effects of ILUMYA include: upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects. You are encouraged to report any negative side effects of ILUMYA to FDA.
What is the difference between Ilumya and Tremfya?
Here we look at how Ilumya and Tremfya are alike and different. Ilumya contains tildrakizumab, which is a type of drug called a monoclonal antibody. Tildrakizumab inhibits (blocks) the activity of a protein called the interleukin-23 (IL-23) molecule. In plaque psoriasis, this molecule is involved in the skin cell buildup that leads to plaques.
What is Ilumya (tildrakizumab-asmn)?
Ilumya (tildrakizumab-asmn) is a brand-name prescription medication that’s used to treat moderate to severe plaque psoriasis. It’s prescribed for adults who are eligible for systemic therapy (drugs given by injection or taken by mouth) or phototherapy (light therapy). Ilumya is a type of drug called a monoclonal antibody.
